Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:17 PM ET 8-K
Loan & Debt Covista Inc. CVSA

Covista $510M Debt Financing with Morgan Stanley Senior Funding, Inc.

Covista Inc. entered into Amendment No. 6 to its existing Credit Agreement to reprice $510 million in outstanding term loans. The amendment reduces the interest rate from Term SOFR plus 2.25% to Term SOFR plus 2.00%, effectively lowering the company's borrowing costs.

Value
$510M
Counterparty
Morgan Stanley Senior Funding, Inc.
4:16 PM ET 8-K
Loan & Debt Solaris Energy Infrastructure, Inc. SEI

Solaris Energy Infrastructure $1.25B Debt Financing with MUFG Securities Americas Inc.

Solaris Energy Infrastructure, LLC, a subsidiary of Solaris Energy Infrastructure, Inc., priced an upsized private placement of $1.25 billion in 7.000% Senior Notes due 2032. The offering was increased from an initial $1.0 billion and is expected to close on October 1, 2026. Net proceeds of approximately $1,227.2 million will be used for general corporate purposes, growth capital expenditures, and fees.

Value
$1.25B
Counterparty
MUFG Securities Americas Inc.
Term
through April 2032
4:16 PM ET 8-K
Leadership Change Farmers & Merchants Bancshares, Inc. FMFG

Farmers & Merchants Bancshares Leadership Change

Farmers and Merchants Bancshares, Inc. has elected Mark C. Krebs to its Board of Directors as a Class I director, effective September 21, 2026. Mr. Krebs previously served as the company's Treasurer and CFO until his retirement in June 2025 and will serve on the Asset/Liability, Investor Relations, and Nominating Committees.

Counterparty
Mark C. Krebs
4:16 PM ET 8-K
Investor Presentation Orange County Bancorp, Inc. OBT

Orange County Bancorp Investor Presentation

Orange County Bancorp, Inc. released an investor presentation deck to be reviewed with analysts and institutional investors at the Stephens Bank Forum 2026 on September 24, 2026. The materials provide updates on the company's operating and growth strategies, as well as its financial performance through the second quarter of 2026.

Counterparty
Stephens Bank Forum 2026
4:16 PM ET 8-K
Financial Results NeoVolta Inc. NEOV

NeoVolta Financial Results

NeoVolta reported fiscal year 2026 revenue of $13.3 million, a 58% increase year-over-year, despite a significant fourth-quarter revenue decline due to residential tax law changes. The company posted a GAAP net loss of $21.5 million for the year as it transitions into a multi-market energy storage platform through its NeoVolta Power manufacturing joint venture.

Term
FY2026
Earnings call
Sep 23, 2026, 5:00 PM ET
4:16 PM ET 8-K
Loan & Debt Jazz Pharmaceuticals plc JAZZ

Jazz Pharmaceuticals $1.9B Debt Financing with Bank of America, N.A.

Jazz Pharmaceuticals' subsidiary, Jazz Financing Lux S.à r.l., entered into a repricing amendment to its credit agreement to refinance $1.895 billion in outstanding term loans. The new Tranche B-3 Dollar Term Loans extend the maturity date from May 2028 to May 2033 and reduce the interest rate margin by 50 basis points to Term SOFR plus 1.75%.

Value
$1.9B
Counterparty
Bank of America, N.A.
Term
through May 2033
4:16 PM ET 8-K
Stock Plan Amendment Healthstream Inc HSTM

Healthstream Stock Plan Amendment

HealthStream's Compensation Committee approved special grants of time-based and performance-based restricted share units (RSUs) to its named executive officers under the 2022 Omnibus Incentive Plan. The grants, which include awards to CEO Robert A. Frist, Jr. and CFO Scott A. Roberts, are designed to incentivize future performance and retention with vesting schedules extending through 2030.

Term
4 years
4:15 PM ET 8-K
Capital Raise Blue Owl Credit Income Corp. OCIC

Blue Owl Credit Income Capital Raise of $1.75M

Blue Owl Credit Income Corp. sold 191,466 unregistered Class I common shares for $1.75 million in a private placement to feeder vehicles. The company also provided an update on its continuous public offering, which has raised approximately $22.5 billion in total proceeds to date across its public and private offerings.

Value
$1.75M
Counterparty
feeder vehicles
4:14 PM ET 8-K
Court & Legal Update Sarepta Therapeutics, Inc. SRPT

Sarepta Therapeutics Court & Legal Update

Sarepta Therapeutics entered into a settlement agreement with REGENXBIO, the University of Pennsylvania, and Catalent to resolve pending patent infringement litigation regarding the '274 and '617 patents. Sarepta will pay a lump sum of $39.0 million to REGENXBIO in exchange for a release of claims and a covenant not to sue regarding Sarepta's gene therapy products using the AAVrh74-based capsid, including ELEVIDYS. The settlement resolves all pending litigations with prejudice and includes no admission of liability.

Counterparty
REGENXBIO Inc.
4:14 PM ET 8-K
Capital Raise Leader's Advantage Acquisition Corp. LEDR

Leader's Advantage Acquisition Capital Raise of $150M

Leader’s Advantage Acquisition Corp. consummated its initial public offering (IPO) of 15,000,000 units at $10.00 per unit, generating gross proceeds of $150 million. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with the units trading on Nasdaq under the symbol LEDRU. The company has granted underwriters a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments.

Value
$150M
Counterparty
Clear Street LLC
4:12 PM ET 8-K
Clinical Trial Data Arcturus Therapeutics Holdings Inc. ARCT

Arcturus Therapeutics Holdings Clinical Trial Data

Arcturus Therapeutics released Phase 2 clinical data for ARCT-810, its mRNA-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency. The company also provided a strategic update on its broader mRNA delivery platform and technology pipeline.

4:11 PM ET 8-K
Loan & Debt Ready Capital Corp RC

Ready Capital $100M Debt Financing with U.S. Bank Trust Company, National Association

Ready Capital Corporation entered into a supplemental indenture to amend the terms of its $100 million 7.375% Senior Notes due 2027. The amendment, approved by a majority of noteholders, relaxes the Recourse Debt to Equity Ratio to 2.0 to 1.0 and adjusts the minimum Consolidated Net Asset Value covenant to $1.2 billion plus equity activity adjustments.

Value
$100M
Counterparty
U.S. Bank Trust Company, National Association
Term
through 2027
4:11 PM ET 8-K
Reverse Stock Split Vsee Health, Inc. VSEE

Vsee Health Reverse Stock Split

VSee Health, Inc. has filed a Certificate of Amendment to effect a 1-for-80 reverse stock split of its common stock, effective September 23, 2026. The stock will begin trading on a split-adjusted basis on September 24, 2026, under a new CUSIP number. No fractional shares will be issued, with any resulting fractions rounded up to the next whole number.

4:10 PM ET 8-K
Dividend Blue Owl Technology Income Corp. OTIC

Blue Owl Technology Income Dividend

Blue Owl Technology Income Corp. declared monthly distributions for its Class S, Class D, and Class I shares, with a gross distribution of $0.074775 per share payable in October and November 2026. The filing also provided a routine update on its continuous public offering, which has raised approximately $4.07 billion to date, and reported an August 31, 2026 net asset value (NAV) of $9.75 per share across all classes.

4:07 PM ET 8-K
Reverse Stock Split Marimed Inc. MRMD

Marimed Reverse Stock Split

MariMed Inc. has filed a definitive proxy statement for a special meeting of stockholders to seek approval for a reverse stock split at a ratio between 1-for-50 and 1-for-100. The move is intended to increase the share price to satisfy listing requirements for a potential move to a major U.S. national securities exchange. The special meeting is scheduled for October 28, 2026.

4:06 PM ET 8-K
Other 8-K Filing Gossamer Bio, Inc. GOSS

Gossamer Bio Other 8-K Filing

Gossamer Bio has submitted its first New Drug Application (NDA) to the FDA for seralutinib for the treatment of pulmonary arterial hypertension (PAH). The submission is supported by data from the Phase 3 PROSERA and Phase 2 TORREY studies, following a Pre-NDA meeting with the regulator in June 2026. The FDA is expected to determine whether to accept the application for filing later this year.

Counterparty
FDA
4:06 PM ET 8-K
Clinical Trial Data Evommune, Inc. EVMN

Evommune Clinical Trial Data

Evommune announced that Phase 2a proof-of-concept data for EVO301, its IL-18 binding protein candidate for moderate-to-severe atopic dermatitis, will be presented in a late-breaking oral session at the EADV 2026 Congress. The presentation will build on topline results reported earlier in the year as the company prepares to initiate a Phase 2b dose-ranging study in mid-2027.

Counterparty
European Academy of Dermatology & Venereology (EADV)
4:06 PM ET 8-K
Capacity Expansion Evofem Biosciences, Inc. EVFM

Evofem Biosciences Capacity Expansion

Evofem Biosciences entered into a manufacturing agreement with Zhaoke Ophthalmology Pharmaceutical Limited to establish a second production source for its contraceptive gel, PHEXX. The expansion is designed to enhance supply chain flexibility and is expected to reduce unit costs by 40% or more once regulatory approval for the new facility is obtained.

Counterparty
Zhaoke Ophthalmology Pharmaceutical Limited
4:06 PM ET 8-K
Shareholder Meeting FutureFuel Corp. FF

FutureFuel Shareholder Meeting

FutureFuel Corp. held its 2026 annual stockholders' meeting on September 22, 2026, where shareholders elected Paul A. Novelly, II and Richard P. Rowe to the board of directors. Stockholders also approved executive compensation on an advisory basis and ratified the appointment of Grant Thornton LLP as the company's independent auditor for the fiscal year ending December 31, 2026.

4:06 PM ET 8-K
Business Update AtlasClear Holdings, Inc. ATCH

AtlasClear Holdings Business Update

AtlasClear Holdings announced preliminary unaudited results for fiscal year 2026, reporting expected revenue of $20.1 million, an 85% increase year-over-year. The company achieved its second consecutive year of positive net income at approximately $2.0 million and more than doubled its cash position to $15.4 million. The results were driven by significant growth in stock locate fees and commissions without the need for dilutive capital raises.

Term
FY2026
4:06 PM ET 8-K
Other 8-K Filing Eva Live Inc GOAI

Eva Live Other 8-K Filing

Eva Live Inc. entered into an Equity Purchase Agreement with Hudson Global Ventures, LLC, establishing a committed equity facility of up to $10 million. The company has the right, but not the obligation, to direct the investor to purchase shares at $2.00 per share from time to time, subject to the effectiveness of a resale registration statement.

Counterparty
Hudson Global Ventures, LLC
Term
Commitment Period
4:06 PM ET 8-K
Loan & Debt Mobile Infrastructure Corp BEEP

Mobile Infrastructure Debt Financing Update with Harvest Small Cap Partners

Mobile Infrastructure Corporation entered into a fifth amendment to its credit agreement with Harvest Small Cap Partners to extend the maturity date from September 30, 2026, to December 31, 2026. The amendment is a related party transaction as Board Co-Chair Jeffrey Osher manages the investment manager for the lenders. Additionally, the company declared monthly dividends for its Series A and Series 1 Preferred Stock.

Counterparty
Harvest Small Cap Partners, L.P. and Harvest Small Cap Partners Master, Ltd.
Term
through Dec 31, 2026
4:06 PM ET 8-K
Court & Legal Update Regenxbio Inc. RGNX

Regenxbio Court & Legal Update

REGENXBIO and UPenn entered into a settlement agreement with Sarepta Therapeutics and Catalent to resolve all patent infringement litigation regarding U.S. Patent Nos. 10,526,617 and 11,680,274. Sarepta will pay REGENXBIO $39.0 million and receive a covenant not to sue for future claims relating to gene therapy products using an AAVrh74-based capsid, including ELEVIDYS.

Counterparty
Sarepta Therapeutics, Inc.
4:05 PM ET 8-K
Executive Compensation Flywire Corp FLYW

Flywire Executive Compensation

Flywire Corporation appointed Sabrina Farmer to its Board of Directors and the Nominating and Corporate Governance Committee, effective September 22, 2026. Ms. Farmer will receive an annual cash retainer of $35,000 plus $4,000 for committee service, and was granted an initial restricted stock unit award valued at $350,000. She brings extensive technology leadership experience from previous roles at Microsoft, GitLab, and Google.

Counterparty
Sabrina Farmer
4:02 PM ET 8-K
Clinical Trial Data Longeveron Inc. LGVN

Longeveron Clinical Trial Data

Longeveron announced that its Phase 2b ELPIS II trial evaluating laromestrocel for hypoplastic left heart syndrome (HLHS) failed to meet its primary efficacy endpoint of change in right ventricular ejection fraction at 12 months. Despite the failure, the company noted a favorable safety profile and plans to discuss exploratory clinical outcomes with the FDA to determine potential next steps. Consequently, the company has initiated cost containment measures and is exploring options to maximize shareholder value.

4:01 PM ET 8-K
Financial Results Stitch Fix, Inc. SFIX

Stitch Fix Financial Results

Stitch Fix reported Q4 net revenue of $324.4 million, up 4.2% year-over-year, and full-year revenue of $1.35 billion, up 6.4%. Despite the revenue growth, the company reported a full-year net loss of $12.6 million and provided a cautious FY2027 outlook citing a challenging consumer environment and lower active client counts.

Term
Q4 2026 and FY2026
Earnings call
Sep 23, 2026, 5:00 PM ET

“Fiscal 2026 was a transformative year for Stitch Fix. We closed the year as a significantly healthier business, with a strengthened operating foundation, along with a reimagined client experience and more compelling assortment.”

Matt Baer, CEO, Stitch Fix
4:01 PM ET 8-K
Business Update EQT Private Equity Co LLC

EQT Private Equity Co Business Update

EQT Private Equity Company LLC reported its Transactional Net Asset Value (NAV) as of August 31, 2026, totaling approximately $1.1 billion across various share classes. The filing provides a breakdown of NAV components, including $971.7 million in assets at fair value and $138.7 million in cash, alongside a reconciliation to GAAP Net Asset Value. This periodic update is used to determine the price for share sales and repurchases but does not include a formal GAAP income statement.

4:01 PM ET 8-K
Business Update EQT Infrastructure Co LLC

EQT Infrastructure Co Business Update

EQT Infrastructure Company LLC reported its transactional net asset value (NAV) per share for various share classes as of August 31, 2026, with values ranging from $25.26 to $29.40. The company disclosed a total transactional NAV of approximately $1.08 billion, supported by assets at fair value of $670.2 million and cash equivalents of $416.7 million. This periodic update provides investors with the current valuation used for share sales and repurchases.

Term
August 31, 2026
3:55 PM ET 8-K
Executive Compensation Central Plains Bancshares, Inc. CPBI

Central Plains Bancshares Executive Compensation

Central Plains Bancshares extended the employment agreement for CEO Dannel R. Garness and change in control agreements for CFO Bradley M. Kool and CLO Kurt A. Haecker. The agreements were extended to expire on October 24, 2029, with no other changes to the existing terms.

Term
through Oct 2029
3:54 PM ET 8-K
M&A Deal Apogee Enterprises, Inc. APOG

Apogee Enterprises M&A Deal with GroGlass

Apogee Enterprises completed the acquisition of SIA “Alzette” and its subsidiaries, including GroGlass, a Latvian provider of high-performance anti-reflective glass coatings. The transaction values GroGlass at €62.5 million on a cash-free, debt-free basis, with an additional contingent earnout of up to €10 million based on financial performance over three years. The acquisition was funded through available cash and borrowings under the company's existing revolving credit facility.

Counterparty
GroGlass

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.